Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v10-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2021-11-26 | 2021-09-07 |
| Drug Identification Number | 02013967 | 02013967 |
| Brand name | CLINIMIX E | CLINIMIX E |
| Common or Proper name | CLINIMIX E 5% Amino Acids (Blend B) with Electrolytes in 16.6% Dextrose Injection | CLINIMIX E 5% Amino Acids (Blend B) with Electrolytes in 16.6% Dextrose Injection |
| Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
| Ingredients | L-ARGININE MAGNESIUM CHLORIDE SODIUM CHLORIDE POTASSIUM PHOSPHATE DIBASIC SODIUM ACETATE L-TYROSINE L-PROLINE TRYPTOPHAN L-THREONINE HISTIDINE L-VALINE L-ISOLEUCINE GLYCINE L-ALANINE METHIONINE L-LYSINE HYDROCHLORIDE L-PHENYLALANINE HYDROCHLORIDE L-LEUCINE HYDROCHLORIDE DEXTROSE | L-ARGININE MAGNESIUM CHLORIDE SODIUM CHLORIDE POTASSIUM PHOSPHATE DIBASIC SODIUM ACETATE L-TYROSINE L-PROLINE TRYPTOPHAN L-THREONINE HISTIDINE L-VALINE L-ISOLEUCINE GLYCINE L-ALANINE METHIONINE L-LYSINE HYDROCHLORIDE L-PHENYLALANINE HYDROCHLORIDE L-LEUCINE HYDROCHLORIDE DEXTROSE |
| Strength(s) | 520MG 24MG 58.5MG 261MG 205MG 20MG 210MG 90MG 210MG 220MG 230MG 240MG 1.04G 1.04G 290MG 290MG 310MG 310MG 16.6G | 520MG 24MG 58.5MG 261MG 205MG 20MG 210MG 90MG 210MG 220MG 230MG 240MG 1.04G 1.04G 290MG 290MG 310MG 310MG 16.6G |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1000 mL (JB6771P) | 1000 mL (JB6771P) |
| ATC code | B05BA | B05BA |
| ATC description | I.V. SOLUTIONS | I.V. SOLUTIONS |
| Reason for shortage | Demand increase for the drug. | Shortage of an active ingredient. |
| Anticipated start date | 2021-09-07 | 2021-09-07 |
| Actual start date | 2021-09-07 | 2021-09-07 |
| Estimated end date | 2021-11-25 | Unknown |
| Actual end date | 2021-11-25 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order. | Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order. |
| Health Canada comments |